Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0

作者：

Smit, E. ^{[1
]}

Ahn, M-J ^{[2
]}

Dagogo-Jack, I. ^{[3
]}

Felip, E. ^{[4
]}

Gelsomino, F. ^{[5
]}

Johnson, B. ^{[6
]}

Johnson, M. ^{[7
]}

Negrao, M. V. ^{[8
]}

Offin, M. ^{[9
]}

Ramalingam, S. ^{[10
]}

Sanborn, R. ^{[11
]}

Tsao, A. ^{[8
]}

Wilner, K. ^{[12
]}

Alcasid, A. ^{[13
]}

Usari, T. ^{[14
]}

Zhang, X. ^{[15
]}

Riely, G. ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA

[12] Pfizer, La Jolla, CA USA

[13] Pfizer, Collegeville, PA USA

[14] Pfizer, Milan, Italy

[15] Pfizer, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

non-small cell lung cancer; encorafenib; binimetinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA06.13

引用

页码：S77 / S78

页数：2

共 50 条

[1] Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Riely, G. J.
Ahn, M-J.
Clarke, J.
Dagogo-Jack, I.
Felip, E.
Gelsomino, F.
Goldman, J. W.
Hussein, M.
Johnson, M. L.
Morgensztern, D.
Nadal, E.
Offin, M. D.
Provencio Pulla, M.
Ramalingam, S. S.
Smit, E. F.
Tsao, A. S.
Alcasid, A.
Usari, T.
Wilner, K.
Johnson, B.
ANNALS OF ONCOLOGY, 2024, 35 : 1246 - 1247
[2] Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study
Ramalingam, Suresh S.
Carlisle, Jennifer W.
FUTURE ONCOLOGY, 2024, 20 (33) : 2503 - 2508
[3] Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne S.
Johnson, Melissa Lynne
Gelsomino, Francesco
Esper, Raymond M.
Nadal, Ernest
Offin, Michael
Provencio-Pulla, Mariano
Otterson, Gregory Alan
Dagogo-Jack, Ibiayi
Alcasid, Ann
Usari, Tiziana
Wilner, Keith D.
Pathan, Nuzhat
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
Takashima, Atsuo
Kotani, Daisuke
Kato, Takeshi
Satoh, Taroh
Masuishi, Toshiki
Komatsu, Yoshito
Shiozawa, Manabu
Esaki, Taito
Izawa, Naoki
Takeuchi, Shinji
Bando, Hideaki
Iwasa, Satoru
Hasegawa, Hiroko
Yamaguchi, Toshifumi
Taniguchi, Hiroya
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[5] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
Shahjehan, F.
Kamatham, S.
Chandrasekharan, C.
Kasi, P. M.
DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
[6] A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne
Johnson, Melissa
Gelsomino, Francesco
Esper, Raymond
Nadal, Ernest
Offin, Michael
Provencio, Mariano
Clarke, Jeffrey
Hussein, Maen
Otterson, Gregory A.
Dagogo-Jack, Ibiayi
Goldman, Jonathan W.
Morgensztern, Daniel
Alcasid, Ann
Usari, Tiziana
Wissel, Paul
Wilner, Keith
Pathan, Nuzhat
Tonkovyd, Svitlana
Johnson, Bruce E.
FUTURE ONCOLOGY, 2024, 20 (16) : 1047 - 1055
[7] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
Planchard, David
Besse, Benjamin
Groen, Harry J. M.
Hashemi, Sayed M. S.
Mazieres, Julien
Kim, Tae Min
Quoix, Elisabeth
Souquet, Pierre-Jean
Barlesi, Fabrice
Baik, Christina
Villaruz, Liza C.
Kelly, Ronan J.
Zhang, Shirong
Tan, Monique
Gasal, Eduard
Santarpia, Libero
Johnson, Bruce E.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
[8] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Yamaguchi, Toshifumi
Daisuke, Kotani
Atsuo, Takashima
Takeshi, Kato
Toshiki, Masuishi
Yoshito, Komatsu
Manabu, Shiozawa
Taito, Esaki
Naoki, Izawa
Shinji, Takeuchi
Hideaki, Bando
Satoru, Iwasa
Hiroko, Hasegawa
Taroh, Satoh
Hiroya, Taniguchi
Takayuki, Yoshino
ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
[9] Encorafenib plus cetuximab (EC) plus FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
Tabernero, J.
Yoshino, T.
Kim, T. W.
Yaeger, R.
Desai, J.
Wasan, H. S.
Van Cutsem, E.
Ciardiello, F.
Maughan, T.
Eng, C.
Tie, J.
Elez Fernandez, M. E.
Lonardi, S.
Usari, T.
Hahn, E.
Dychter, S.
Ferrier, G.
Zhang, X.
Kopetz, S.
ANNALS OF ONCOLOGY, 2024, 35 : S435 - S436
[10] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
Aderka, D.
Kopetz, S.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Golden, A.
Edwards, M.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214

← 1 2 3 4 5 →